Working... Menu

Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer (CADENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02547987
Recruitment Status : Recruiting
First Posted : September 14, 2015
Last Update Posted : July 13, 2018
Information provided by (Responsible Party):
Mothaffar Rimawi, Baylor Breast Care Center

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 2019
  Estimated Study Completion Date : September 2021